No Data
No Data
Jiangsu Hengrui Medicine Gets State Administrator Approval for Tumor Drug Clinical Trials
AVIC Securities: The pharmaceutical industry's performance in the third quarter is under pressure, with the total market value of heavyweight holdings by funds increasing.
The demand for blood sector in the biological products sector remains strong, with vaccine sales under pressure due to factors such as previous market consumption; the active pharmaceutical ingredient sector is entering the final stage of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
Patient mortality risk reduced! jiangsu hengrui pharmaceuticals (600276.SH) announced the latest clinical data of Ilixadencel liposomes.
The research results have shown that the combination therapy with Erlotinib liposome (Ⅱ) reduced the risk of death in pancreatic cancer patients by 37% compared to the control group.
Jiangsu Hengrui Pharmaceuticals (600276.SH) has cumulatively repurchased 4.9361 million shares, costing 0.207 billion yuan.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that, as of October 31, 2024, the company has successfully completed centralized competitive bidding...
Jiangsu Hengrui Pharmaceuticals (600276.SH): received notification of approval for clinical trials of drugs.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced on October 28 that the company and its subsidiaries Shanghai Shendi Pharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceuticals Co., Ltd., and Suzhou Shendiya Biomedical received the Drug Clinical Trial Approval Letters for HRS-4642 Injection, Adalimumab Injection, SHR-1826 for Injection, SHR-9839 for Injection, SHR-8068 Injection, and Bevacizumab Injection issued by the National Medical Products Administration, and will conduct clinical trials soon.
The 'Number One in Medicine' intends to go public in Hong Kong! A-shares are on average 96% more expensive than Hong Kong stocks.
According to Bloomberg's news on October 24th, jiangsu hengrui pharmaceuticals is considering a secondary listing in Hong Kong next year, aiming to raise at least $2 billion. jiangsu hengrui pharmaceuticals announced after the market on the same day that in recent years, driven by technology innovation and global strategy, the company has steadily promoted internationalization. To further deepen the company's strategic development goals, the company has recently conducted preliminary work such as research and consultation on financing in overseas capital markets. As of now, the company has not yet determined a specific plan for the relevant matters. As a leading domestic innovative international pharmaceutical company, jiangsu hengrui pharmaceuticals focuses on oncology, metabolic diseases, autoimmune diseases, and respiratory system.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years AgoNo Data
No Data
